Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 90 | ECE2023 | Next issue

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

Card image cap
ECE 2023 will be held in Istanbul, Turkey from 13-16 May 2023. Istanbul is known for its rich culture, historical sites and dynamic nightlife, and we are excited to come together in this city, and look forward to meeting old friends, making new ones, and sharing science, collaborations and ideas.

Oral Communications

Oral Communications 8: Calcium and Bone

ea0090oc8.1 | Oral Communications 8: Calcium and Bone | ECE2023

Clinical picture of early infancy PTH-resistance syndromes: is it time to improve diagnostic criteria?

Del Sindaco Giulia , Pagnano Angela , Berkenou Jugurtha , Ferrante Emanuele , Rothenbuhler Anya , Arosio Maura , Mantovani Giovanna , Linglart Agnes

Since the first description of inactivating PTH/PTHrP signaling disorders (iPPSDs, historically named pseudohypoparathyroidism (PHP)) a remarkable clinical variability was observed, especially in clinical presentation, which seems to be age-dependent. The main clinical features, including PTH resistance, brachydactyly and short stature, develop during mid and late childhood, whilst minor clinical features such as a round face, rapid weight gain and subclinical hypothyroidism a...

ea0090oc8.2 | Oral Communications 8: Calcium and Bone | ECE2023

Eneboparatide, a Novel PTH-1 Receptor Agonist, Has No Impact on Bone Parameters Following Chronic Treatment of Non-Human Primates

Ravel Guillaume , Delale Thomas , Milano Stephane , Chirat Sophie , Verset Michael , Latronico Emilie , Allas Soraya , Culler Michael D.

Eneboparatide (AZP-3601) is a novel, synthetic, 36-amino-acid peptide agonist of the parathyroid hormone type 1 receptor (PTHR1), with potent selectivity for the R0 conformation. This results in prolonged calcemic responses, while having a short circulating half-life. Eneboparatide is being developed for the treatment of chronic hypoparathyroidism (cHP). Studies in hypoparathyroid animal models and, most recently, in hypoparathyroid patients, have demonstrated that eneboparati...

ea0090oc8.3 | Oral Communications 8: Calcium and Bone | ECE2023

The thiazide challenge test to differentiate between primary hyperparathyroidism and secondary hyperparathyroidism due to idiopathic hypercalciuria.

Verly Ewout , Verroken Charlotte , Lapauw Bruno

Background: Treatment of primary hyperparathyroidism (PHPT) and secondary hyperparathyroidism due to idiopathic hypercalciuria (SHPT-IH) is markedly different. Nevertheless, differentiating one from another remains a challenge and robust diagnostic tools are lacking. The thiazide challenge test (TCT) has been proposed as a means to aid clinicians in their decision making. However, evidence supporting its use is scarce.Materials and Methods: We performed ...

ea0090oc8.4 | Oral Communications 8: Calcium and Bone | ECE2023

Bone mineral density and fracture status of differentiated thyroid cancer patients under TSH suppression treatment

Yavuz Dilek Gogas , Dincer Yazan Ceyda , Hekimsoy Zeliha , Aydin Kadriye , Gokkaya Naile , Ersoy Canan , I mge Aydogan Berna , Akalin Aysen , Topaloğlu Omercan , Ademoglu Dilekci Esra Nur , Cansu Guven Baris , Can Bulent , Gungor Kagan , Evran Mehtap , Keskin Lezzan , Uc Ziynet Alphan , Iyidir Ozlem , Ozsari Levent , Garip Tayfun , Elbuken Gulsah , Mert Meral , Pekkolay Zafer , Canturk Zeynep , Ilgin Can , Kutbay Nilufer Ozdemir , Yorulmaz Goknur , Kalkan Ahmet Toygar , Aydoğan Unsal Yasemin , Yay Adnan , Karagun Barış , Bozkur Evin

Aim: Thyroid Stimulating Hormone (TSH) suppression treatment may have a detrimental effect on bone tissue in differentiated thyroid cancer (DTC) patients. The current study aimed to investigate vertebral fracture, bone mineral density measurements, and TSH levels in DTC patients under levothyroxine (LT4) suppression treatment after total thyroidectomy and/or radioiodine ablation therapy in a multicentric setting.Material and Method: This multicentric cro...

ea0090oc8.5 | Oral Communications 8: Calcium and Bone | ECE2023

A vitamin D receptor antagonist as a potent and safe treatment for Idiopathic Infantile Hypercalcemia

Rovito Daniela , Lutzing Regis , Keime Celine , Metzger Daniel , Linglart Agnes , Laverny Gilles

Idiopathic Infantile Hypercalcemia (IIH) is a rare inborn form of severe vitamin D hypersensitivity, with an estimated incidence of 1:33.000 live birth and a high degree of misdiagnosis. Since the identification of CYP24A1 loss-of-function variants inducing IIH in 2011, over 41 pathogenic variants have been described, and represent the major genetic drivers of IIH1. CYP24A1 encodes the main catalytic hydroxylase of the bioactive form of vitamin D (1,25D3). Upon bind...

ea0090oc8.6 | Oral Communications 8: Calcium and Bone | ECE2023

Skeletal phenotypes in postmenopausal women with primary hyperparathyroidism (PHPT)

Corbetta Sabrina , Gianotti Laura , Castellano Elena , Raineri Francesca , Munari Elisabetta , Guabello Gregorio , Pierotti Laura , Dinoi Elisa , Valentina Simone Della , Cetani Filomena

Current clinical presentation of PHPT is mild disease with an increased risk of fragility fractures. PHPT predominantly occurs in postmenopausal women, who have an increased risk of osteoporosis and fractures due to ageing and loss of estrogen.Aims: To explore skeletal phenotypes in postmenopausal women affected by PHPT with a wide clinical and biochemical spectrum of disease.Patients: Postmenopausal (at least 5 years from last men...